Helps keep you in range, day and night1,2
No multiple daily injections, tubes, or fingersticks*
Cleared for people with type 1 diabetes ages 2 years and older
The best of both worlds.
No need to compromise.
Long gone are the days of choosing between glucose results from an Automated Insulin Delivery System and freedom of a tubeless device. With Omnipod 5, you can have the best of both worlds, all in one.
More time in range
Clinical study participants showed improved time in range by 3.7 hours per day in children (2.6 hours per day in children ages 2-5.9 years) and 2.2 hours per day in adolescents and adults.1,2
Lower A1C
Clinical study participants experienced a reduction in A1C of 0.71% in children (0.5% in children ages 2-5.9 years) and 0.38% in adolescents and adults.1,2
Adapted to you
Omnipod 5 adapts with every Pod change to meet your unique insulin needs and adjusts insulin using a customized Target Glucose, not a range.
In a 3-month clinical study, 3 cases of severe hypoglycemia and 1 case of diabetic ketoacidosis (DKA) were reported in children and adults/adolescents during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction.2
Innovation at your fingertips
Omnipod 5 boasts outstanding design and engineering, recognized by the CES Innovation Awards in 2022.
Using SmartAdjust™ technology, the Pod and compatible CGM are in constant communication, enabling automatic insulin adjustments to help improve time in range.1,2 And, you can control it all from your fingertips with the Omnipod 5 App on a compatible smartphone.†
†For a list of compatible smartphone devices visit omnipod.com/compatibility
![Omnipod 5 Pod left with CES badge to the upper right](/sites/default/files/2024-06/4-col_Omnipod-5_Pod-left_CES-badge_600x728.png)
![Omnipod 5 Pod left with CES badge to the upper right](/sites/default/files/2024-06/4-col_Omnipod-5_Pod-left_CES-badge_600x728.png)
The support you need to succeed
With Omnipod, you get more than just an insulin management system, you also get:
- Access to a 24/7 support team
- Training sessions and materials to get you started
- User guides, “how-to” videos, and resources to help along the way
- A community of Podders just like you, sharing tips and experiences for simplifying life with diabetes
When you get started on Omnipod, you’re no longer on your own managing your Type 1 diabetes. With a team of dedicated support professionals and seemingly endless resources at your fingertips, we make it our mission to help you be successful.
Hear real stories
“Having control over my diabetes and my numbers—I’ve found this new confidence that I didn’t have before.”
Morgan M.
Omnipod 5 User
Get Started Today!
Omnipod 5 is now integrated with Dexcom G6 and Dexcom G7. If you are new to Omnipod, you may have coverage for Omnipod 5 with Dexcom G7 integration through select mail-order pharmacies.
Choose a path below and answer a few questions to find out which Omnipod product# is best for you. It’s that easy.
Once complete, a member of the Omnipod Pharmacy support team** will reach out with your expected copay and free trial†† eligibility.
I’d like to check my coverage
Find out your estimated copay
I'd like a free trial of Omnipod††
Take the Pod for a test drive
If you are already on Omnipod 5, visit the New Omnipod 5 Compatible Devices page to learn more.
1. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021).
Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NоvоRаpid®, Humаlоg®, and Аdmеlоg®.The Omnipod 5 Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydrохуurеа as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia. The OmnipodPromise™ allows users to start on Omnipod DASH through the pharmacy and upgrade to any future Omnipod technology for no additional cost, when covered by insurance. The OmnipodPromise™ is only available for users with valid prescription and coverage through their pharmacy benefit. Upgrades subject to user's insurance coverage and product cost is subject to copays as required by insurance coverage.
1. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021).
#Available products subject to current insurance coverage and product indication for use. Insulet can only support onboarding for those customers within the product indication. The Omnipod® 5 System is currently indicated for use by individuals with type 1 diabetes, 2 years of age and older. Omnipod DASH® is currently indicated for all insulin-requiring users.
**ASPN Pharmacies and its dedicated staff power the Omnipod Pharmacy Support Program. The ASPN team is here for you to check your coverage and help coordinate fulfillment at your pharmacy of choice.
†ASPN Pharmacies and its dedicated staff power the Omnipod Pharmacy Support Program. The ASPN team is here for you to check your coverage and help coordinate fulfillment at your pharmacy of choice.
†† Omnipod DASH® 30-Day Free Trial
Terms and Conditions
1. Program Eligibility
Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod DASH 30-day Free Trial Program (the “Program”) is open to patients who have a valid Omnipod DASH prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. The Program is open only to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod® 5, Omnipod DASH or Omnipod Insulin Management System.
This offer is not valid for participants whose Omnipod DASH prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs, or where prohibited by law. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Please contact Insulet Customer Support at 1-800-591-3455 for details.
2. Program Details
With this program, Participants may be eligible to receive a 30-day supply of Omnipod DASH products at no cost for them. Eligible participants have two (2) options, based on the following:
• A participant shall sign the 30-day Omnipod DASH Free Trial Acknowledgement through the appropriate platform provided by Insulet’s pharmacy partner.
• Once Insulet, or its pharmacy partner, has received the request, including a valid prescription for the Omnipod DASH Intro Kit and Omnipod DASH Pods, the participant’s benefits will be checked by Insulet or its pharmacy partner.
• If the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet, or its pharmacy partner, shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod DASH 30-day initial shipment, in accordance with Section 3, below.
• If the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod DASH Intro Kit, in accordance with Section 4, below.
• For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.
• Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.
Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time.
3. Copay Card
Should participant be deemed eligible to receive an Omnipod DASH Copay Card, participant shall receive electronically one (1) Omnipod DASH Copay Card, valid for a single use, in the amount required for the participant to procure a 30-day supply of Omnipod DASH Pods at a participating pharmacy. In addition, Insulet’s pharmacy partners shall ship, at no cost to participant, one (1) Omnipod DASH Starter Kit, which shall include:
• One (1) Omnipod DASH Personal Diabetes Manager (PDM)
• One (1) Omnipod DASH User Guide
• One (1) PDM charging cable
The Omnipod DASH Starter Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Starter Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Starter Kit and to verify the content of the Starter Kit.
4. Product Dispense
Should participant be deemed eligible to receive a one-time dispense of Omnipod DASH Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod DASH Intro Kit, which shall include:
• One (1) Omnipod DASH PDM
• Eleven (11) Omnipod DASH Pods
• One (1) Omnipod DASH User Guide
• One (1) PDM charging cable
The Omnipod DASH Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.
†† Omnipod® 5 10-Day Free Trial
Terms and Conditions
1. Program Eligibility
Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5 10-day Free Trial Program (the “Program”) is open to patients who have a valid Omnipod 5 and Dexcom G6 or Dexcom G7 prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH®️ or Omnipod Insulin Management System.
This offer is not valid for participants whose Omnipod 5, Dexcom G6 or Dexcom G7 prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program. Please contact Insulet Customer Support at 1-800-591-3455 for details.
2. Program Details
With this program, Participants may be eligible to receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following:
• A participant shall sign the Try Omnipod 5 Free Trial Acknowledgement through the appropriate platform provided by Insulet.
• Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.
• IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.
• IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.
• For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.
• Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.
• In order to use the Omnipod 5 System in Automated Mode, the User must also procure a Dexcom G6 Continuous Glucose Monitor System. For more information about how to obtain a 10-day supply of Dexcom G6, please contact Dexcom or click on the following link: http://www.dexcom.com/SampleOP5.
Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time.
3. Copay Card
Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include:
• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable
4. Product Dispense
Should participant be deemed eligible to receive a one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall include:
• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable
The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.
Omnipod® 5 Coverage Claims
1. Over 90% of commercially insured patients have pharmacy benefit coverage for Omnipod 5, the majority of which have preferred tier access
Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods in commercial channel only. Majority defined as >70%. Source: Managed Markets Insights & Technology, LLC. Data as of June 1 2023
2. Omnipod 5 has over 90% coverage, representing over 300 million covered lives
Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods. Source: Insulet Data on File As of June 1 2023.
3. More than 26,000 US pharmacies have dispensed Omnipod 5
Reflects total Omnipod 5 unique pharmacy dispensing count. Source: Insulet Data on File as of June 1, 2023
4. More than half of covered Omnipod 5 scripts are filled within 24 hours
Calculated based on the proportion of script fills within 24-hour look forward period out of all script fills within a 90-day look forward period among all new to brand claims for the Omnipod 5 G6 Intro Kit from October 2022 to March 2023. Excludes claim reversals. Source: IQVIA Payer Control Library
5. Over 80% of covered Omnipod 5 scripts are filled within a week
Calculated based on the proportion of script fills within 7 days look forward period out of all script fills within a 90-day look forward period among all new to brand claims for the Omnipod 5 G6 Intro Kit from October 2022 to March 2023. Excludes claim reversals. Source: IQVIA Payer Control Library